Cargando…
Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
Malignant pleural mesothelioma is a rare malignant disease that in the majority of cases is associated with asbestos exposure. The incidence in Europe is about 20 per million inhabitants and it is increasing worldwide. Initial symptoms are shortness of breath, pleural effusion, cough, and chest pain...
Autores principales: | Geltner, Christian, Errhalt, Peter, Baumgartner, Bernhard, Ambrosch, Gerhard, Machan, Barbara, Eckmayr, Josef, Klikovits, Thomas, Hoda, Mir Alireza, Popper, Helmut, Klepetko, Walter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033998/ https://www.ncbi.nlm.nih.gov/pubmed/27619223 http://dx.doi.org/10.1007/s00508-016-1080-z |
Ejemplares similares
-
Management of malignant pleural mesothelioma—part 2: therapeutic approaches: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Hoda, Mir Alireza, et al.
Publicado: (2016) -
Management of malignant pleural mesothelioma – part 3: Data from the Austrian Mesothelioma Interest Group (AMIG) database
por: Klikovits, Thomas, et al.
Publicado: (2016) -
Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014) -
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015) -
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)